Following the rapid approval of enzalutamide (Xtandi®; formerly known as MDV3100) by the U.S. Food & Drug Administration (FDA), the developers have moved just as rapidly to be able to make the product available to men with metastatic, castration-resistant prostate cancer who have received prior treatment with docetaxel-based chemotherapy. According to a joint media release by Astellas and Medivation, prescriptions for enzalutamide can be filled as of today, just 13 days after the FDA approval. The media release goes on to say that enzalutamide will be “distributed through a network of specialty pharmacies and specialty distributors.”
In addition, the companies have announced the
… launch of a comprehensive patient access support program for [enzalutamide] to ensure patients who are prescribed [the product] can access the drug in a timely manner. The new program, XTANDI Access ServicesSM, will provide access and reimbursement support to physicians and patients and assist eligible patients without insurance. Examples of support available through this program include help with benefit verification and prior authorization, patient referral to independent non-profit organizations that can assist with out-of-pocket expenses, and prescription forwarding to specialty pharmacies in the network.
XTANDI Access Services may be contacted in the USA Monday through Friday from 9:00 a.m. to 8:00 p.m. ET at 1-855-898-2634 or by visiting the XTANDI Access Services web site.